By far the two most common prostate diseases are prostatitis and benign hyperplasia (BPH). Prostatitis can be complicated by BPH or accompany it with periodic exacerbations. Drug therapy is an important component in the general treatment of prostate diseases. Additionally, treatment often ends in defeat due to improper therapy, missed medications, and, when the condition is alleviated, ignoring the disease.
Therefore, 20-30% of patients are not satisfied with the treatment, do not experience a decrease in symptoms of urinary disorders and an improvement in the quality of life. Most likely, this is due to an incorrect assessment of lower urinary tract function in men with BPH and, consequently, to the choice of inappropriate treatment.
As you know, prostatitis is acute and chronic (CP), bacterial and abacterial.
Prostatitis in%
- acute bacterial prostatitis - 5-10%;
- chronic bacterial prostatitis - 6-10%;
- chronic abacterial prostatitis - 80-90%, including prostatodynia - 20-30%.
The most common is chronic abacterial prostatitis, which must be controlled and prevented promptly with and without BPH.
The main drugs for the treatment of BPH and chronic prostatitis:
- 5a-reductase inhibitors (finasteride, dutasteride);
- α-blockers (doxazosin, tamsulosin);
- herbal medicine (Sabal palm extract);
- antibiotics;
- amino acid complexes;
- animal organ extracts (prostate extract);
- entomotherapy drugs (products derived from insects).
At the same time, in 13-30% of the effect of the use of α-blockers does not occur within 3 months of treatment - further therapy with drugs of this group is not recommended.
When prescribing finasteride, the doctor must be prepared for the fact that the most significant side effects of the drug: impotence, decreased libido, decreased ejaculate volume can lead to self-withdrawal of the drug by the patient.
Treatment of BPH and prostatitis is an important and not completely resolved urological problem.
Frequent exacerbations of PC in the absence of indications for surgery on the prostate gland force the doctor to use additional methods in drug treatment. Often, the presence of concomitant PC aggravates the course of BPH, because inflammation in 80% of cases is in the prostate gland with benign hyperplasia.
Modern medicine offers us new opportunities for the treatment of CP and BPH and for the prevention of exacerbations.